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PIN11
A COST—EFFECTIVENESS ANALYSIS MODEL FOR
TREATMENT OF CANDIDIASIS AND INVASIVE
ASPERGILLOSIS IN MEXICO
Mould Quevedo JF, Contreras I, García—Contreras F, Nevarez A,
Constantino—Casas P, Garduño J
Social Security Mexican Institute, México D.F, México D.F, Mexico
OBJECTIVES: The purpose of this research is to estimate the
incremental cost–effectiveness ratio (ICER) in Mexican patients
with candidiasis and aspergillosis treated within voriconazole,
amphotericin B and caspofungine. METHODS: It has been
carried out a cost–effectiveness analysis based on a decision
model represented with a decision tree describing multiple ther-
apeutic options together with the obtained clinical results and
the associated costs. The data come from clinical literature for
treatment of candidiasis and invasive aspergillosis in immun-
odepressed patients. Effectiveness measure was the number of
patients with therapeutic success. Costs were taken from hospi-
tal records and expert opinion. The perspective was that of the
National health provider (only direct medical costs) and the time
horizon of the research is of 3 months. The sensitivity analysis
was probabilistic and acceptability curves were constructed.
RESULTS: On a deterministic analysis, three months expected
medical care costs per patient with candidiasis were: US$42.743
for caspofungine, US$30.972 for voriconazole and US$36.736
for amphotericin B. The costs per patient with aspergillosis were:
US$49.962 for caspofungine, US$57.378 for voriconazole and
US$72.834 for amphotericin B. From a hypothetical patient
cohort of 1.000 patients with candidiasis, the ICER was
US$272.597 when voriconazole was used against amphotericin
B (US$ 272.6 per patient). The ICER in the aspergillosis model
was US$206.071 when voriconazole was used against ampho-
tericin B (US$ 206.1 per patient). Acceptability curves showed
that voriconazole was the antifungal treatment most cost–
effective in comparison with the two other treatments with 
a mean of 70% of certainty (with independence of the willing-
ness to pay amount). CONCLUSIONS: The use of voriconazole
in the treatment of candidiasis and invasive aspergillosis is a
more cost–effective therapeutic alternative than amphotericin B
and caspofungine, therefore, voriconazole should be the option
to be used as the ﬁrst line treatment in the Mexican health
system.
PIN12
INFANTILE GASTROENTERITIS IN THE COMMUNITY: A COST
OF ILLNESS STUDY
Lorgelly PK1, Joshi D1, Iturriza Gómara M2, Flood C3, Hughes CA4,
Dalrymple J5, Gray J2, Mugford M1
1University of East Anglia, Norwich, Norfolk, UK; 2Health Protection
Agency, London, London, UK; 3City University, London, London, UK;
4Fakenham Medical Practice, Fakenham, Norfolk, UK; 5Drayton
Surgery, Norwich, Norfolk, UK
OBJECTIVE: To assess the economic burden of gastroenteritis
and, in particular, rotavirus-associated disease among children
aged ﬁve years old and under, from the perspective of the health
service, parents and society. METHOD: Over a period of three
rotavirus seasons, stool samples were collected from 223 chil-
dren who presented at GP surgeries with diarrhoea and vomit-
ing. Parents were asked to complete a questionnaire detailing
severity of illness, health care resource use, personal medical
expenses, changes in child care patterns and associated costs, and
lost income due to their child’s illness. Data were analysed as a
whole to establish the cost of illness of gastroenteritis and sepa-
rately in terms of rotavirus and other viral strains. RESULTS: A
total of 48% of the sample had rotavirus acute gastroenteritis;
a further 21% had other virus-associated gastrointestinal
disease. The average total cost of a child presenting with gas-
troenteritis and rotavirus-gastroenteritis ranged between
£60–£176 and £59–£169 per episode, respectively, depending on
the perspective. The annual cost of ‘normal’ childhood illness
was estimated to be between £205 and £323. Given the preva-
lence and severity of the disease, the estimate additional burden
of gastroenteritis to society is £75.2 million per year, and for
rotavirus gastroenteritis it is £57.2 million per year. CONCLU-
SIONS: Due to the nature and prevalence of rotavirus the total
burden of illness is considerable. As well as being a major incon-
venience to parents and children, it would appear that there is a
considerable amount of cost shifting between the health service,
parents and society. Some of the economic cost of the illness may
be constrained with an immunisation programme; work is cur-
rently being undertaken to model the cost effectiveness of vacci-
nation within the UK context.
PIN13
ANNUAL COST FOR THE TREATMENT OF PATIENTS
HOSPITALIZED WITH METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS IN THE UNITED STATES
Rojas EG, Liu LZ
Pﬁzer Global Pharmaceuticals, New York, NY, USA
OBJECTIVES: To estimate the nationwide annual cost for the
treatment of patients hospitalized with methicillin-resistant
Staphylococcus aureus (MRSA) infections in the United States.
METHODS: An extensive literature search was conducted in
order to identify recent studies estimating the direct medical costs
associated with MRSA infections in US hospitals. The range of
the annual cost of MRSA infections was constructed by multi-
plying the estimated number of annual discharges due to MRSA
infections by the highest and lowest cost per case estimates 
of MRSA bacteremia and S aureus pneumonia infections.
RESULTS: CDC estimated that in 2000 approximately 290,000
US patients were hospitalized with an S aureus infection and that
41.5%, or 120,000 of these were MRSA infections. The most
common types of MRSA infections are skin and skin structure
infections (SSSI), bacteremia, and lower respiratory tract infec-
tions. Abramson and Sexton estimated the direct medical costs
associated with MRSA bacteremia to be $27,083 per case. Enge-
mann et al. estimated the direct medical costs associated with an
SSSI due to MRSA to be $28,308 per case. Rubin et al. estimated
the direct medical costs associated with S aureus pneumonia to
be $34,900 per case. The average cost of an MRSA-related infec-
tion, based on cited studies, ranged from $27,083 to $34,900
per case. Assuming 120,000 annual MRSA infection related hos-
pital discharges, we estimate that the annual nationwide cost for
the treatment of patients hospitalized with an MRSA infection
in the US to be in the range of $3.2 billion to 4.2 billion. CON-
CLUSION: The annual cost for the treatment of MRSA infec-
tions incurs a signiﬁcant economic burden on the US health care
system. Strategies to minimize hospital costs relating to MRSA
infection should be critical to the management of this economic
burden placed on US hospitals.
PIN14
OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN 
NON-ELDERLY ADULTS: UTILIZATION AND COST
Rose J1,Asche CV2, Singer ME1
1Case School of Medicine, Cleveland, OH, USA; 2University of Utah,
Salt Lake City, UT, USA
OBJECTIVE: To examine utilization and cost of services in the
outpatient treatment of community-acquired pneumonia (CAP)
among non-elderly adults. METHODS: We analyzed claims
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from eight managed care organizations. Index claims were out-
patient or emergency department visits in 1999–2001 by indi-
viduals aged 25–64 with a primary diagnosis of pneumonia,
antibiotic prescription within three-days, chest x-ray on index
date, continuous enrollment for 12-months prior, 30-days after
index visit. Exclusion criteria: antibiotic prescription, pneumo-
nia diagnosis, or hospitalization in prior 30-days; initial therapy
with multiple antibiotics; in prior 12-months residence in a 
long-term care facility or diagnosis of lung cancer, secondary
malignancy, HIV/AIDS, cystic ﬁbrosis, immunodeﬁciency. 
We considered the following comorbid illnesses: chronic liver, 
renal or lung disease; cerebrovascular disease; cardiac disease;
diabetes mellitus; malignancy. Follow-up claims were considered
CAP-related if the primary diagnosis, using the Clinical 
Classiﬁcations Software, was pneumonia; septicemia; pleurisy,
pneumothorax or pulmonary collapse; respiratory failure, insuf-
ﬁciency or arrest; other lower respiratory infection. RESULTS:
In total, 5748 cases met criteria; 79.7% had no comorbidities,
16.8% had one comorbidity, and 3.5% had two or more comor-
bidities. Mean total charges were $955.97: 48.2% inpatient,
25.2% outpatient, 13.4% outpatient testing and diagnostics,
7.5% antibiotic prescriptions, 5.8% emergency department,
13.9% presenting to the emergency department had initial mean
charges of $360.48 compared with mean initial charges for out-
patients of $167.89. In total, 50.0% utilized follow-up services
with 3.0% requiring hospitalization. Mean total charges for
those eventually hospitalized were $16,436.23 compared with
$673.71 for the 13.1% of patients who failed initial treatment
but were not hospitalized, and $431.91 for the 78.0% of patients
requiring no additional antibiotics. Number of comorbidities
was strongly associated (p < 0.0001) with charges: $888.19 for
those without comorbidities vs. $1734.37 for those with multi-
ple comorbidities. CONCLUSION: Cost of outpatient CAP for
non-elderly adults is large even for those without comorbid
illness.
PIN15
IMPACT OF COMPLICATED SKIN AND SOFT TISSUE
INFECTIONS ON INPATIENT COSTS FOR AN ACADEMIC
MEDICAL CENTER
Patel N1, Goldfarb N1, Hartmann CW1, Maio V1, Horn DL2, Pizzi L1
1Jefferson Medical College, Philadelphia, PA, USA; 2Thomas Jefferson
University, Philadelphia, PA, USA
OBJECTIVES: To determine the additional costs and lengths of
stay (LOS) attributable to complicated skin and soft tissue infec-
tions (cSSI) for patients admitted to Thomas Jefferson University
Hospital, an urban academic tertiary care hospital. METHODS:
All patients admitted between January 1, 2003 and December
31, 2003 were identiﬁed using the hospital billing system.
Patients with a potential cSSI were identiﬁed using the speciﬁc
ICD-9 diagnosis codes. Costs of care and lengths of stay, based
on the hospital’s true cost accounting system, were compared by
Diagnosis Related Group (DRG) between the cSSI population
and the non-cSSI population. RESULTS: Of the 33,764 patient
discharges in 2003, 1,883 (5.5%) included one of the cSSI diag-
nosis codes; these encompassed 225 DRGs. The mean cost for
cSSI cases was $20,965 higher than for non-cSSI cases, and mean
LOS was ten days higher for cSSI cases. For surgical and medical
DRGs, mean cost of cSSI added $42,563 onto the cost for cases
in surgical DRGs compared to an average increase of $10,048
added to cost of medical DRGs. Differences in costs and LOS
were observed in analyses by Major Disease Categories (MDCs)
and individual DRGs as well. For MDCs, myeloproliferative dis-
orders, multiple trauma, and diseases of the nervous system,
costs were $68,027, $48,286, and $27,496, higher for the cSSI
cases, respectively. This difference was also reﬂected in additional
days of stay of 22, 11, and 14 days, respectively. For patients
with cSSI, the three speciﬁc DRGs responsible for the maximum
total health care dollars expended were bone marrow trans-
plants, rehabilitation, and small and large bowel procedures.
CONCLUSIONS: cSSIs signiﬁcantly increase hospital resource
consumption and costs. The difference in costs is especially pro-
nounced for patients undergoing surgical procedures. Results
suggest that measures taken to avoid or more effectively treat
cSSIs could yield signiﬁcant savings to hospitals.
PIN16
COST-UTILITY OF CHRONIC HEPATITIS “C” TREATMENT
WITH THYMOSIN ALPHA 1 IN MEXICO
Nevárez-Sida A, García-Contreras F, Constantino-Casas P,
Castro-Rios A, Mould J, Garduño-Espinosa J
Mexican Institute of Social Security, Mexico City, Mexico
OBJECTIVE: To estimate cost-utility of the following alterna-
tives in the treatment of chronic hepatitis C (CHC) in the
Mexican Institute of Social Security (IMSS): peginterferon,
peginterferon plus ribavirin, peginterferon plus ribavirin plus
thymosin alpha-1 and ﬁnally, not using any drug. METHODS:
In Mexico, more that one million persons are infected with CHC
virus and 80% of them develop chronic infection that might lead
to hepatic cirrhosis and other complications that affect quality
of life and costs of health care institutions. Cost-utility analysis
was carried out using institutional perspective and time horizon
of 45 years, discount rate of 3% for both, costs and effective-
ness. The base case was a 30-year-old man with CHC without
hepatic cirrhosis or cancer and cost and effectiveness data were
taken from literature, a Mexican expert panel and an on-going
clinical trial, not yet reported. Effectiveness data are reported in
QALYs and costs in 2004 USD. A decision tree using a Bayesian
approach and a Markov model were developed. Sensitivity
analysis was univariate, bivariate, threshold and probabilistic.
Acceptability curves and health net beneﬁts were estimated.
RESULTS: Triple therapy (peginterferon plus ribavirin plus thy-
mosin alpha-1) was dominant over the rest of alternatives costing
$1802 per QALY, while peginterferon plus ribavirin $2275 per
QALY and peginterferon only $2927 per QALY. Not using any
drug was the most costly alternative with $4201 per QALY. Sen-
sitivity analysis conﬁrmed the strength of the base study. Triple
therapy was not dominated in any comparative case. CON-
CLUSIONS: Triple therapy had the best cost-utility ratio and not
using any drug was the opposite, most expensive and with less
utility than all the compared alternatives. Although triple
therapy is initially very expensive, it provides the highest gains
in the long run, both in the improvement of quality of life and
in saving costs.
PIN17
A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE
IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS
Yeh WS, Skrepnek GH,Armstrong EP, Malone DC
University of Arizona College of Pharmacy,Tucson, AZ, USA
OBJECTIVES: This study investigated the effect of using differ-
ent utilities for a cost-utility analysis comparing peginterferon
alpha-2b plus ribavirin, interferon alpha-2b plus ribavirin, and
no treatment for chronic hepatitis C from a U.S. payer’s per-
spective. METHODS: A Markov model was developed to sim-
ulate the lifetime disease progression of hepatitis C virus (HCV)
for a 45-year-old male. The analysis was conducted by stratify-
ing HCV genotypes. Health-state utilities were obtained from
previously published literature. Standard gamble patient-elicited
utilities were used as the base case. Five other expert-estimated
